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ABSTRACT
Objective: Analyse 2-year outcomes after MitraClip
therapy and identify predictors of outcome.
Methods: Consecutive patients (n=74) undergoing
MitraClip therapy were included in the MitraSWISS
registry and followed prospectively.
Results: A reduction of mitral regurgitation (MR) to
≤ mild was achieved in 32 (43%) patients and to
moderate in 31 (42%) patients; 16/63 (25%) patients
with initially successful treatment developed recurrent
moderate to severe or severe MR during the first year
and only 1 patient did so during the second year. At
2 years, moderate or less MR was more frequently
present in patients with a transmitral mean gradient
<3 mm Hg at baseline (73% vs 23%, p < 0.01) and in
patients with a left atrial volume index (LAVI) <50 mL/m2
at baseline (86% vs 52%, p=0.03). More than mild MR
post MitraClip, N-terminal probrain natriuretic peptide
≥5000 ng/L at baseline, chronic obstructive pulmonary
disease (COPD) and chronic kidney disease (CKD) were
associated with reduced survival.
Conclusions: A mean transmitral gradient <3 mm Hg
at baseline, an LAVI <50 mL/m2, the absence of COPD
and CKD, and reduction of MR to less than moderate
were associated with favourable outcome. Given a
suitable anatomy, such patients may be excellent
candidates for MitraClip therapy. Between 1 and
2 years follow-up, clinical and echocardiographic
outcomes were stable, suggesting favourable, long-
term durability of the device.
INTRODUCTION
Mitral regurgitation (MR) is present in about
10% of patients >75 years of age and is the
second most frequent valve disease in
Europe that requires surgery.1–3 Some of
these elderly patients with moderate to
severe or severe MR are at high or even pro-
hibitive surgical risk. The MitraClip device
(Abbott Vascular, Menlo Park, California,
USA) is a less invasive alternative to open
heart surgery. The device achieves a reduc-
tion of MR by approximating the two mitral
valve leaﬂets. Previous publications have
shown that MR can be successfully reduced
in the majority of patients up to 1 year after
the procedure.4–9 Initially, the Endovascular
Valve Edge-to-Edge Repair study (EVEREST)
criteria were established and used for patient
selection,10 but many registries did include
patients who did not strictly apply these cri-
teria. Currently, two of the most important
open questions are long-term durability of
the procedure and patient selection. To
answer these questions, we analysed 2-year
outcomes of consecutive patients undergoing
MitraClip therapy and aimed to identify pre-
dictors of outcome.
METHODS
Study population
Between February 2009 and December 2012,
a total of 155 patients treated by MitraClip
KEY MESSAGES
▸ Clinical and echocardiographic outcomes
between 1 and 2 years were stable, suggesting
favourable, long-term durability of the MitraClip
procedure.
▸ Patients with a mean transmitral gradient <3
mm Hg, an LAVI <50 mL/m2, without chronic
obstructive pulmonary disease and chronic
kidney disease had favourable outcomes and
may thus be good candidates for the MitraClip
procedure.
▸ Since patients with residual moderate (2+) mitral
regurgitation had worse outcome compared to
patients with none/mild mitral regurgitation, the
definition of procedural success may need to be
re-evaluated.
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were included in the MitraSWISS registry. A total of 74
patients included between February 2009 and March
2011 who were treated at three Swiss centres (Cantonal
Hospital Lucerne, Cardiocentro Ticino and University
Hospital Zurich, Switzerland) had reached 2-year
follow-up. These patients were analysed in the present
study. All patients provided written informed consent.
Patient selection
Prior to the intervention, all patients were discussed by
an interdisciplinary heart team. All patients had moder-
ate to severe (3+) or severe (4+) MR on screening echo-
cardiography. Patients were considered for MitraClip
therapy if they had a high surgical risk deﬁned by a
logistic European System for Cardiac Operative Risk
Evaluation (EuroSCORE) mortality >15% and/or add-
itional surgical risk factors such as frailty, porcelain aorta
or prior radiotherapy of the chest. The criteria applied
in EVEREST were used as a reference but not as abso-
lute inclusion or exclusion criteria.10 In particular,
patients with ﬂail leaﬂets were included even if they had
a ﬂail gap >10 mm, as long as the leaﬂets were approxi-
mating at least once during the cardiac cycle. In case of
a functional MR, a leaﬂet coaptation length of <2 mm
was not considered an exclusion criterion, as long as the
leaﬂet margins were parallel for a short distance.
Exclusion criteria included calciﬁcation or thickening of
the posterior annulus reducing the visibility of the pos-
terior leaﬂet. Also, patients with a very lateral regurgita-
tion were excluded due to the risk of interference with
the chordae.
Procedure, data collection and definitions
The MitraClip procedure has been described elsewhere
previously.11 12 Patients were evaluated at baseline, at dis-
charge and at 1 month, 6 months, 1 year and 2 years post
MitraClip. All patients underwent clinical assessment and
transthoracic echocardiography at each visit. A subset of
patients (n=18) also underwent serial 6 min walk tests.
Data were entered into a dedicated, prospective database.
Two-year follow-up was complete in 71/74 (96%) patients.
Three patients were lost to follow-up. Echocardiography
was performed according to the guidelines of the
American Society of Echocardiography.13 MR severity was
graded as none, mild (1+), moderate (2+), moderate to
severe (3+) and severe (4+).10 14 A successful procedure
was deﬁned as a reduction of MR to ≤ moderate (2+ or
less).12 Left ventricular ejection fraction (LV-EF) and left
atrial volume index (LAVI) were calculated using the
biplane Simpson’s method. Pulmonary pressure was calcu-
lated using transthoracic echocardiography. Chronic
kidney disease (CKD) was deﬁned as a baseline glomeru-
lar ﬁltration rate <60 mL/min.
Statistical analysis
Continuous variables were described using means±SD.
Categorical variables were described by frequencies and
percentages. Differences between independent groups
were tested using the χ2 test for categorical variables or
the t test. In cases where the samples were paired, the
paired t test was used. Survival rates at 2 years were
graphed using the Kaplan-Meier method. A Cox regres-
sion model was used to estimate HRs and 95% CIs of
baseline characteristics on mortality. Owing to the rela-
tively low number of patients, no multivariable analyses
were performed in the present study. Analyses were con-
ducted with IBM SPSS Statistics V.18 (IBM Corporation,
Somers, New York, USA) and tested using two-sided tests
at a signiﬁcance level of 0.05.
RESULTS
A total of 74 patients with a mean age of 72±12 years
underwent MitraClip therapy for severe (n=48, 65%) and
moderate-to-severe (n=26, 35%) MR. The original
EVEREST criteria were met by 56 patients (76%). MR was
classiﬁed as functional in 46 (62%) patients and degenera-
tive in 28 (38%) patients. Compared to degenerative MR,
patients with functional MR had a higher logistic
EuroSCORE, presented more frequently with coronary
artery disease, CKD, atrial ﬁbrillation and had a lower ejec-
tion fraction and larger left ventricles. Baseline character-
istics are shown in table 1.
Procedural and in-hospital data are summarised in
table 2. One clip was implanted in 42 (57%) patients,
two clips in 27 (39%) patients and three clips in 2 (3%)
patients. In three patients (4%), no clip was implanted
due to intraprocedural complications. A total of six
patients (8%) had bleeding requiring transfusion, and
one (1%) patient had a pericardial tamponade after
rupture of the left atrium. There were no strokes.
The procedural success rate was 63/74 (85%) patients
with an immediate reduction of MR to none or mild in
32 (43%) patients and moderate in 31 (42%) patients.
The procedural success rate did not differ between
patients who met the EVEREST criteria (47/56, 84%)
and those who did not (16/18, 89%, p=0.61).
Table 3 lists the management and outcomes of unsuc-
cessful procedures. The mean transmitral gradient
increased from 2.0±1.1 mm Hg at baseline to 4.0
±3.1 mmHg before discharge (p<0.01). Overall
in-hospital mortality was 4.1% (3/74). In-hospital mortality
was 0% (0/63) in patients with procedural success and
27% (3/11) in those without procedural success (p<0.01).
MR severity
MR was reduced to ≤ moderate in 63 (85%) patients
(37 (80%) patients with functional MR and 26 (93%)
with degenerative MR). Of these, 17 patients (27%)
developed recurrent moderate to severe (3+) or severe
(4+) MR during the ﬁrst year post MitraClip. Only one
additional patient developed recurrent 3+ or 4+ MR
during the second year (table 4). At 2-year follow-up,
MR was ≤ moderate in 41 (58%) patients, more than
moderate in 12 (17%) patients and 18 (25%) of the
patients had died (ﬁgure 1). There was no signiﬁcant
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difference between patients with functional and degen-
erative MR. At 2 years, ≤ moderate MR was more fre-
quently present in patients with a transmitral mean
gradient <3 mm Hg at baseline (35/48, 74%) than in
those with a gradient ≥3 mm Hg (5/22, 23%, p<0.01)
and in patients with an LAVI <50 mL/m2 at baseline
(12/14, 86%) than in those with an LAVI ≥50 mL/m2
(23/44, 52%, p=0.03). An LAVI ≥50 mL/m2 was more
frequently present in patients with CKD, atrial ﬁbrilla-
tion, a higher logistic EuroSCORE and a higher
pulmonary artery pressure. A mean transmitral gradient
≥3 mm Hg was more frequently found in patients with a
smaller annulus diameter.
Survival
Survival rates were 96%, 81% and 75% at 30 days, 1 year
and 2 years, respectively. Cause of death was heart
failure in 10 patients, exacerbated chronic obstructive
pulmonary disease (COPD) in two patients, sepsis in two
patients and unknown in four patients. A total of 15
Table 1 Baseline characteristics
Variable (n=74)
All patients
(n=74)
Functional
MR (n=46)
Degenerative
MR (n=28) p Value*
Age (years) 72±12 71±13 73±12 0.58
Female sex (%) 20 (27%) 12 (26%) 8 (29%) 0.82
Logistic EuroSCORE (%) 21±17 28±20 15±10 <0.01
MR severity
Severe 48 (65%) 26 (57%) 22 (79%) 0.05
Moderate-severe 26 (35%) 20 (44%) 6 (21%)
Coronary artery disease (%) 28 (38%) 32 (70%) 6 (21%) <0.01
COPD (%) 16 (22%) 10 (22%) 6 (21%) 0.98
Chronic kidney disease (%) 35 (47%) 28 (61%) 7 (25%) <0.01
Atrial fibrillation (%) 26 (35%) 23 (50%) 3 (11%) <0.01
LV-EF (%) 47±19 36±15 64±10 <0.01
LV-EDV (mL) 161±96 185±109 120±43 <0.01
Mitral valve annulus (4Ch, mm) 42±6 42±7 41±5 0.66
Mean transmitral valve gradient
(mm Hg)
2.3±1.3 2.2±1.4 2.5±1.1 0.43
LAVI (mL/m2) 61±26 66±29 53±18 0.09
PASP (mm Hg) 48±16 48±14 47±18 0.70
More than mild TR 16 (22%) 14 (30%) 2 (7%) <0.01
*p Values for comparisons between patients with functional and degenerative MR.
4Ch, four chamber view; COPD, chronic obstructive pulmonary disease; EuroSCORE, European System for Cardiac Operative Risk
Evaluation; LAVI, left atrial volume index; LV-EDV, left ventricular end-diastolic volume; LV-EF, left ventricular ejection fraction; MR, mitral
regurgitation; PASP, pulmonary artery systolic pressure; TR, tricuspid regurgitation.
Table 2 Procedural characteristics
Variable All patients (n=74) Functional MR (n=46) Degenerative MR (n=28) p Value*
Number of clips implanted
0 3 (4%) 3 (7%) 0 (0%) 0.32
1 42 (57%) 26 (57%) 16 (57%)
2 27 (37%) 15 (33%) 12 (43%)
3 2 (3%) 2 (4%) 0 (0%)
MR post procedure†
None 2 (3%) 2 (4%) 0 (0%) 0.34
Mild 30 (57%) 18 (39%) 12 (43%)
Moderate 31 (42%) 17 (37%) 14 (50%)
Moderate-severe 5 (7%) 3 (7%) 2 (7%)
Severe 5 (7%) 5 (11%) 0 (0%)
Transmitral gradient (mm Hg) 4.0±2.9 4.0±3.1 4.1±2.7 0.89
LV-EF (%) 47±17 36±13 62±9 <0.01
PASP (mm Hg) 40±13 41±13 38±13 0.37
In-hospital mortality 3 (4%) 3 (7%) 0 (0%) 0.29
*p Values for comparisons between patients with functional and degenerative MR.
†Information not available in one patient who died intraprocedural.
LV-EF, left ventricular ejection fraction; MR, mitral regurgitation; PASP, pulmonary artery systolic pressure.
Toggweiler S, Zuber M, Sürder D, et al. Open Heart 2014;1:e000056. doi:10.1136/openhrt-2014-000056 3
Valvular heart disease
group.bmj.com on February 12, 2015 - Published by http://openheart.bmj.com/Downloaded from 
patients had an LV-EF <30% at baseline. Survival rate at
2 years was 72% in patients with functional MR and 82%
in those with degenerative MR (p=0.31). Survival rate at
2 years was 73% in those with an LV-EF <30% at baseline
(n=15) and 76% in those with an LV-EF ≥30% (n=59,
p=0.81). Signiﬁcant predictors of reduced survival were
residual MR severity post MitraClip (ﬁgure 2),
N-terminal probrain natriuretic peptide (NT-proBNP)
≥5000 ng/L at baseline, the presence of COPD and the
presence of CKD (table 5).
Partial clip detachment
At 2 years, partial clip detachment had occurred in
seven (10%) patients. Most of these events occurred
within the ﬁrst 30 days (n=4), or between 30 days and
1 year (n=2). There was one patient with a partial clip
detachment 2 years post procedure. In 5/7 (71%)
patients, partial clip detachment resulted in 3+ or 4+
MR. A re-do MitraClip procedure was performed in ﬁve
patients, whereas the remaining two were treated
medically. The re-do procedure reduced MR to ≤ mod-
erate in 2/5 (40%) patients. The remaining three
patients had persistent moderate to severe or severe MR.
No differences were noted between patients with func-
tional or degenerative mitral valve disease in terms of
survival, partial clip detachment and need for surgical
repair.
Functional and echocardiographic outcome
At 2 years, 37 patients (53%) were in the New York
Heart Association (NYHA) class I or II, 13 (19%) in
Table 3 Management and outcome of patients with unsuccessful procedures (n=11)
Event Management Outcome
Chordal rupture (no clip implanted) Surgical MVR Death 5 days post procedure
Papillary muscle rupture (no clip implanted) Medical
treatment
Intraprocedural death
Reduction of MR to 3+ Medical
treatment
Death 44 days post procedure
Reduction of MR to 3+ Medical
treatment
Patient alive at 2 years
No relevant reduction of MR with 1 clip; impossible to implant more
clips
Medical
treatment
Death 57 days post procedure
Clip only attached on 1 leaflet; not possible to grasp both leaflets Medical
treatment
Death 106 days post
procedure
Reduction to 3+ MR Medical
treatment
Death 103 days post
procedure
Reduction to 3+ MR Re-do procedure Patient alive at 2 years
No reduction of MR Medical
treatment
Patient alive at 2 years
Not possible to grasp both leaflets (no clip implanted) Surgical MVR Patient alive at 2 years
Reduction to 3+ MR Medical
treatment
Patient alive at 2 years
MR, mitral regurgitation; MVR, mitral valve replacement.
Table 4 Clinical outcomes 1 and 2 years post MitraClip
Variable
1-year
outcome
2-year
outcome
≤ Moderate MR 41 (58%) 41 (58%)
Mortality 14 (19%) 18 (25%)
Partial clip detachment 6 (8%) 7 (10%)
Re-do MitraClip
procedure
1 (1%) 7 (10%)
Mitral valve surgery 4 (5%) 4 (5%)
NYHA class I or IV 13 (18%) 15 (20%)
MR, mitral regurgitation; NYHA, New York Heart Association.
Figure 1 Severity of MR at BL, and at 1 month, 6 months,
1 year and 2 years post MitraClip. At 2-year follow-up, MR
was ≤ moderate in 58%, more than moderate in 17% and
25% of the patients had died. BL, baseline; MR, mitral
regurgitation.
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class III and 2 (3%) in class IV (ﬁgure 3). Six minutes
walking distance improved from 425±104 m at baseline
to 523±108 m at 2-year follow-up (p<0.01). Pulmonary
artery pressure decreased from 48±16 mm Hg at baseline
to 35±11 mm Hg at 2-year follow-up (p<0.01). Left ven-
tricular end-diastolic volume was 161±96 mL at baseline
and 137±61 mL at 2-year follow-up (p=0.18). LV-EF
remained unchanged. LAVI was 61±26 mL/m2 at base-
line and 55±21 mL/m2 at 2-year follow-up (p=0.54).
DISCUSSION
Long-term clinical follow-up data are essential to judge
the value of percutaneous mitral valve repair with the
MitraClip. This study reports 2-year outcomes of the ﬁrst
74 consecutive patients undergoing MitraClip therapy at
three centres in Switzerland. The procedure successfully
reduced MR to ≤ moderate in 63/74 (85%) patients.
Of those patients with procedural success, 16/63 (25%)
developed recurrent moderate to severe or severe MR
during the ﬁrst year post MitraClip. Only one additional
patient developed moderate to severe or severe MR
during the second year, suggesting that MR grade
remained relatively stable beyond 1-year post procedure.
As a consequence, the proportion of patients with
≤ moderate MR was 58% after both 1 and 2 years
(43/74). No clip embolised during the 2-year period,
but at 2 years, partial clip detachment had occurred in
seven patients, in six patients during the ﬁrst year and
only in one patient during the second year.
Nevertheless, the majority of re-do procedures were per-
formed during the second year. Most of these patients
were clinically compensated and a trial with medical
therapy was usually performed. Treatment of MR with
the MitraClip device resulted in less symptoms and an
increase in 6 min walking distance, a decrease in pul-
monary pressure, left ventricular end-diastolic volume
and LAVI. LV-EF remained unchanged.
Mortality was low between 1 and 2 years (4/74
patients). However, overall 2-year morality was relatively
high (25%) due to inclusion of elderly patients with
comorbidities and/or low LV-EF. For comparison, the
estimated 2-year mortality rate of people with similar age
in Switzerland is about 7%.15
Predictors of clinical efficacy and survival
Currently, one of the remaining open questions is which
patients should be selected for MitraClip therapy.
Initially, the EVEREST criteria were used to select
patients.10 We believe that the EVEREST inclusion cri-
teria describe a population with a high likelihood of pro-
cedural success. However, carefully selected patients not
fulﬁlling the EVEREST criteria may be treated equally
successfully. In the present study, 18 (24%) patients did
not meet the EVEREST criteria, but the procedural
success rate was not lower in these patients. We identi-
ﬁed a transmitral mean gradient <3 mm Hg at baseline
and an LAVI <50 mL/m2 at baseline to be associated
with a persistent clinical success (ie, persistent reduction
of MR to ≤ moderate). This may be important when
performing echocardiographies to screen patients for
Figure 3 NYHA class over the 2-year study period. At
2 years, 53% of patients were in NYHA class I or II, 19% were
in class III and 3% in class IV. BL, baseline; NYHA, New York
Heart Association.
Table 5 Univariate predictors of survival
Variable HR (95% CI) p Value
Residual MR severity 2.54 (1.45 to 4.46) <0.01
NT-proBNP ≥5000 ng/L 6.18 (1.84 to 20.79) <0.01
COPD 2.36 (1.04 to 5.36) 0.04
Chronic kidney disease 3.29 (1.37 to 7.92) <0.01
COPD, chronic obstructive pulmonary disease; MR, mitral
regurgitation; NT-proBNP, N-terminal probrain natriuretic peptide.
Figure 2 Survival according to residual MR post MitraClip.
Residual more than mild MR post MitraClip was associated
with reduced survival, suggesting that MR should be reduced
as much as possible. MR, mitral regurgitation.
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the MitraClip procedure. Residual MR post MitraClip,
NT-proBNP ≥5000 ng/L at baseline, the presence of
COPD and CKD affected survival and long-term
outcome. Based on our results, MR should be reduced
as much as possible, since residual moderate MR (which
is still considered a procedural success) was associated
with reduced survival compared to residual none/mild
MR. The prognostic value of natriuretic peptides has
been established in many different scenarios.16 17
Comorbidities, in particular COPD and CKD, have been
found to be associated with worse prognosis in patients
undergoing transcatheter aortic valve implantation.18
A low LV-EF <30% is considered as a high risk for
mitral valve reconstruction since the acute rise in after-
load may result in left ventricular deterioration.
Interestingly, a low LV-EF did not affect outcome in the
present study. Survival rate did not differ between
patients with an LV-EF <30% and patients with an LV-EF
≥30% at baseline, although the number of patients with
an LV-EF <30% was low (n=15, 20% of patients). In
future, a score predicting the clinical success of mitral
clipping may be developed, similar to the Wilkins Score
predicting outcome after percutaneous balloon dilation
of the mitral valve.
Comparison to previous studies
To the best of our knowledge, this is the ﬁrst real-world
study with a 2-year follow-up completed in 96% of
patients. Two previous studies have reported outcomes
after MitraClip beyond 12 months. The EVEREST II ran-
domised trial which compared treatment with the
MitraClip to surgery recently published results up to
4 years.19 In accordance with the results of the present
study, they found that the majority of recurrent moder-
ate to severe or severe MR occurred during the ﬁrst year
of follow-up. In line with our study results, only few
patients developed recurrent MR between years 1 and 4.
However, in the EVEREST trials, precise echocardio-
graphic criteria had to be met, thus excluding many
patients who might have potentially beneﬁted from the
MitraClip procedure. In addition, placement of more
than one clip has been increasingly used after the publi-
cation of the EVEREST trial. This may explain the
higher rate of procedural success in the present study
(85% vs 77% in the EVEREST II trial).
Rudolph et al20 reported outcomes of a single-centre
registry. Patients were followed for a median of
13.3 months. They found that in patients with degenera-
tive (primary) MR, Logistic EuroSCORE, a lower
forward stroke volume, left ventricular dysfunction in
patients with coronary artery disease and renal failure
were associated with reduced survival.
The ACCESS-EU study included a total of 567 patients,
of whom 393 (69%) had functional MR.5 Procedural
success was obtained in 91% of patients. Similar to this
study, baseline characteristics differed between patients
with functional and degenerative MR, but outcome at
30 days and 12 months was comparable.
Previous studies have identiﬁed an increase in cardiac
index and a decrease in pulmonary artery and wedge
pressures as predictors of favourable short-term out-
comes.21 22 Two recent publications identiﬁed acute pro-
cedural success and residual discharge MR severity as
predictors of 1-year survival post MitraClip therapy.23 24
However, these variables are all unknown at baseline and
can therefore not serve for patient selection.
Study limitations
These patients represent the early experience of the
three centres, and the level of experience (individual
and overall) has increased since then. With better
patient selection and higher experience, better results
can be anticipated in future. Owing to the relatively low
number of patients, no multivariable analyses were per-
formed in the present study.
Clinical implications and conclusion
Clinical and echocardiographic outcomes were stable
beyond 1 year, suggesting favourable long-term durability
of percutaneous mitral valve reconstruction. Baseline
predictors of favourable outcome were a mean transmi-
tral gradient <3 mm Hg, an LAVI <50 mL/m2, the
absence of COPD and the absence of CKD. These ﬁnd-
ings may have important implications for patient selec-
tion. In addition, patients with moderate MR post
procedure had a worse outcome compared to patients
with none/mild MR. In the light of these results, the
deﬁnition of procedural success may need to be
re-evaluated. In future, improved patient selection,
experience and maybe concomitant utilisation with non-
surgical mitral annuloplasty devices may lead to even
better outcomes and a wider application of the
MitraClip procedure.
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